Program News
News and stories about members of the UNC Lineberger Cancer Therapeutics Research Program
-
Priming the pump for new cancer treatments
UNC Eshelman School of Pharmacy’s Chemical Biology and Medicinal Chemistry Division is a central hub for cancer therapeutics. Its faculty members are studying the chemical and biological mechanisms that promote cancer growth and persistence.
-
Kabanov invested as member of American Academy of Sciences and Letters
UNC Lineberger’s Alexander V. Kabanov, PhD, DSc, was honored by the American Academy of Sciences and Letters in recognition of his outstanding scholarly achievement in nanomedicine and drug delivery research.
-
Targeted treatment for cancer is providing “wonderful tomorrows”
Personalized cancer care – and lots of positivity – are helping Mark Braswell, who was diagnosed with stage 4 non-small cell lung cancer.
-
UNC Lineberger continues its national leadership in breast cancer research
UNC Lineberger researchers are leading next-generation clinical breast cancer trials as part of a national project using cutting-edge technologies to track tumor changes in real time.
-
‘If you’re trying to make a difference in cancer, you can’t go slow’
Chad Pecot, MD, leads cancer RNA research at UNC Lineberger, creating innovative therapies and promising treatment strategies for multiple cancer mutations.
-
UNC Lineberger faculty members presenting Het Talks during University Research Week
Three UNC Lineberger members will share their research during the Het Talks at UNC-Chapel Hill’s University Research Week, Oct. 20-24.
-
Researchers awarded $11.2M grant to close endometrial cancer survival gap
The National Cancer Institute has awarded a Cancer Health Disparities Specialized Program of Research Excellence (SPORE) in Endometrial Cancer grant to UNC Lineberger’s Victoria Bae-Jump, MD, PhD, and Hazel Nichols, PhD.
-
Cancer center relaunches Grand Rounds to connect clinicians and researchers across the health system
UNC Lineberger has relaunched its Cancer Grand Rounds lecture series to encourage dialogue across specialties, improve patient outcomes and promote collaborative research.
-
UNC Lineberger launches study to evaluate multi-cancer detection tests
UNC Lineberger is recruiting participants for the Vanguard Study, which is evaluating a new type of blood test that screens for several types of cancer. This is the first study of the Cancer Screening Research Network.
-
UNC Lineberger launches groundbreaking trial for rare, aggressive thyroid cancer
UNC Lineberger has launched a first-of-its-kind clinical trial aimed at improving outcomes in BRAF wildtype anaplastic thyroid cancer (ATC). Siddharth Sheth, DO, MPH, and Jeffrey Blumberg, MD, FACS, are leading the trial.
-
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes
Chad Pecot, MD, and colleagues have developed a “two-in-one” molecule that targets hard-to-treat cancers by silencing two key genes — KRAS and MYC — while also delivering drugs directly to affected tumors.
-
Faith, advocacy and determination shaped patient’s journey to survivorship
Kwame Kwofie, a citizen of Ghana, found himself in uncharted territory when he faced a head and neck cancer diagnosis thousands of miles away from home.
-
UNC Lineberger expands access to cancer clinical trials across North Carolina
UNC Lineberger’s J. Kaitlin Morrison, PhD, and Carrie Lee, MD, PhD, launched a study to investigate whether UNC Health can successfully conduct hybrid cancer clinical trials across the state.
-
UNC honors three cancer center members with 2025 Hettleman Prizes
Sarah Cohen, PhD, Marissa Hall, PhD, and Lindsey James, PhD, were awarded Hettleman Prizes, which recognizes UNC-Chapel Hill early-career faculty who exemplify groundbreaking and innovative research.
-
Carey named a ‘Giant’ of breast cancer care
Lisa Carey, MD, ScM, FASCO, was honored by OncLive as one of its 2025 Giants of Cancer Care for her significant contributions advancing the treatment and study of breast cancer.